TVGNW 0.07 Tevogen Bio Holdings Inc.
| Range: | 0.0449-0.0903 | Vol Avg: | 0 | Last Div: | 0 | Changes: | 0.02 |
| Beta: | 0.31 | Cap: | 0.27B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Thu Jan 01 1970 | Empoloyees: | 17 | ||
| CUSIP: | CIK: | 0001860871 | ISIN: | US88165K1198 | Country: | US | |
| CEO: | Dr. Ryan H. Saadi M.D., M.P.H, M.P.H. | Website: | https://tevogen.com | ||||
Tevogen Bio Holdings Inc. operates as a clinical-stage biotechnology company that develops off-the-shelf precision T cell therapeutics in virology, oncology, and neurology. Its lead investigational precision T cell product, TVGN 489, is designed to address the unmet need of acute-risk COVID-19 patients, as well as a subset of patients suffering from long COVID. The company is based in Warren, New Jersey.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow